The five-year data reinforces CARVYKTI's differentiation in the multiple myeloma CAR-T market, but the small sample size (n=20) limits statistical significance. Monitor upcoming CARTITUDE-4 and CARTITUDE-5 readouts for larger datasets that could drive label expansion and revenue acceleration.
Price Chart
Executive Summary
Legend Biotech announced five-year follow-up data from CARTITUDE-2 Cohort A showing that 50% of RRMM patients remained progression-free and alive five years after a single CARVYKTI infusion, with a 69.2% five-year overall survival rate. The data strengthens the curative potential narrative for CARVYKTI in earlier-line treatment but comes from a small cohort (n=20) and does not change near-term revenue or regulatory trajectory.
Key Facts
- 50% of patients (10/20) remained alive and progression-free at 5 years after a single CARVYKTI infusion without maintenance therapy
- Five-year overall survival rate was 69.2%
- Median PFS was 60.5 months; median overall survival was not reached
- Median follow-up of 60.7 months in CARTITUDE-2 Cohort A (n=20)
- No new CAR T-cell-related neurotoxicity reported with longer follow-up
- One patient developed acute myeloid leukemia; two deaths occurred due to progressive disease and new cancer
- Data presented at 2026 IMS Annual Meeting (Abstract #PA-288)
Financial Impact
No financial figures provided in the filing; the data supports the long-term efficacy profile of CARVYKTI, which could support market share expansion in earlier-line RRMM but has no immediate revenue impact.
Risk Factors
- Small cohort size (n=20) limits generalizability of results
- Secondary malignancies (AML) and deaths observed in long-term follow-up
- Competitive pressure from other BCMA-targeted therapies (e.g., Abecma, Tecvayli)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006229 |
| Document: f6k_092426.htm | 0001171843-26-006229 |
| Document: 0001171843-26-006229-index-headers.html | 0001171843-26-006229 |
| Document: 0001171843-26-006229-index.html | 0001171843-26-006229 |
| Document: 0001171843-26-006229.txt | 0001171843-26-006229 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers